key: cord-0746999-e1ei458z
authors: Daher, Ayham; Balfanz, Paul; Cornelissen, Christian; Müller, Annegret; Bergs, Ingmar; Marx, Nikolaus; Müller-Wieland, Dirk; Hartmann, Bojan; Dreher, Michael; Müller, Tobias
title: Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae
date: 2020-10-20
journal: Respir Med
DOI: 10.1016/j.rmed.2020.106197
sha: 1cb640acc9b24b12a7a95f89c89eb688b8dd7a7c
doc_id: 746999
cord_uid: e1ei458z

BACKGROUND: Since December 2019 the novel coronavirus disease 2019 (COVID-19) has been burdening all health systems worldwide. However, pulmonary and extrapulmonary sequelae of COVID-19 after recovery from the acute disease are unknown. MATERIAL AND METHODS: Hospitalized COVID-19 patients not requiring mechanical ventilation were included and followed 6 weeks after discharge. Body plethysmography, lung diffusion capacity (DLco), blood gas analysis (ABG), 6-min walk test (6MWT), echocardiography, and laboratory tests were performed. Quality of life (QoL), depression, and anxiety were assessed using validated questionnaires. RESULTS: 33 patients with severe disease were included. Patients were discharged without prophylactic anticoagulation. At follow-up there were no thromboembolic complications in any patient. 11 patients (33%) had dyspnea, 11 (33%) had cough, and 15 (45%) suffered from symptoms of fatigue. Pulmonary function tests including ABG did not reveal any limitations (TLC: median = 94% of predicted [IQR:85–105]; VC: 93% [78–101]; FEV1: 95% [72–103]; FEV1/FVC 79% [76–85]; PaO2: 72 mmHg [67–79]; PaCO2: 38 mmHg (Xu et al., 2020; Tian et al., 2020; Huang et al., 2020; Ware, 2013) [35-38], except for slightly reduced DLco (77% [69–95]). There were no echocardiographic impairments. 6MWT distance was reduced in most patients without oxygen desaturation. According to standardized questionnaires, patients suffered from reduced QoL, mainly due to decreased mobility (SGRQ activity score: 54 [19–78]). There were no indicators for depression or anxiety (PHQ-9: 7 [4], [5], [6], [7], [8], [9], [10], [11]( Mizumoto et al., 2020; Kimball et al., 2020; Sakurai et al., 2020; Tabata et al., 2020; Wu and McGoogan, 2020; Richardson et al., 2020; Lewnard et al., 2020; Wang et al., 2020) [4], [5], [6], [7], [8], [9], [10], [11]4-11, GAD-7: 4 [1], [2], [3], [4], [5], [6], [7], [8], [9]( Lu et al., 2020; Zhou et al., 2020; Zhu et al., 2020; Mizumoto et al., 2020; Kimball et al., 2020; Sakurai et al., 2020; Tabata et al., 2020; Wu and McGoogan, 2020; Richardson et al., 2020) [1], [2], [3], [4], [5], [6], [7], [8], [9]1-9, respectively). CONCLUSIONS: Hospitalized patients with severe COVID-19, who did not require mechanical ventilation, are unlikely to develop pulmonary long-term impairments, thromboembolic complications or cardiac impairments after discharge but frequently suffer from symptoms of fatigue.

Since December 2019 a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been causing a rapidly spreading international outbreak; which has been burdening all health systems over the globe through a new form of pneumonia called coronavirus disease 2019 . [1] [2] [3] Although the majority of infected patients has asymptomatic infection or mild disease; [4] [5] [6] [7] [8] the overall numbers of severe cases and the fatality rates are unfortunately high. [8] [9] [10] Additionally, the complication rates as well as extrapulmonary organ involvement (e.g. thromboembolic complications, cardiac and neurological involvement) are apparently higher in patients suffering from COVID-19 compared to other acute respiratory diseases. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, even asymptomatic patients may have objective abnormalities, like ground-glass opacities on computed tomography (CT) and disturbances in gas exchange. [21, 22] Recovery time from the acute disease appears to be around two weeks in mild and three to six weeks in severe disease, [23] though there is not enough information about the possible sequelae after recovery from acute disease. An analysis of 110 survivors with showed impairments in diffusing capacity for carbon monoxide (DLco) and some restrictive ventilatory defects at the time of discharge from hospital, [24] whereas the clinical relevance and the course of these abnormalities following discharge, and their impact on quality of life have not been studied so far. A systematic review and meta-analysis of the literature on patients with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) after hospitalization showed impaired DLco and reduced exercise capacity (6-minute walking distance) at 6 months with limited improvement beyond that. [25] Furthermore, survivors of SARS and MERS had a considerable prevalence of psychological impairments such as post-traumatic stress disorder (PTSD), depression, anxiety and reduced quality of life beyond 6 months. [25] However, such testing has not been performed in patients with COVID-19 yet, although this could provide a better understanding of this emerging disease and could help to ensure an adequate and timely management of significant health limitations with the aim of restoring premorbid quality of life. [25] The aim of this study was to investigate pulmonary impairments, as well as the prevalence of other organ dysfunctions and psychological disorders in patients with COVID-19 six weeks after discharge from hospital.

J o u r n a l P r e -p r o o f  The present prospective study included 33 consecutive patients who had been hospitalized   due to COVID-19 confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) in a respiratory tract sample. All patients were admitted to the isolation ward between February and May 2020. Only symptomatic patients with severe disease needing hospitalization were included. We excluded patients with Acute Respiratory Distress Syndrome (ARDS) who needed mechanical ventilation in the intensive care unit (ICU) during their stay. At discharge, patients got routine follow-up appointments in the pulmonary disease outpatient clinic six weeks after discharge.

The protocol for this study was approved by the local ethics committee (EK 080/20). All investigations were performed in accordance with the ethical standards laid down in the Declaration of Helsinki in its latest revision. Written informed consent was obtained from all patients prior to inclusion.

Demographic data, disease history, coexisting medical conditions, presence of chronic respiratory failure, smoking history, and medication history were recorded for all patients (Table 1 ). Symptoms at admission and a detailed history of present symptoms were also documented.

Patients were assessed for eligibility on the basis of a positive RT-PCR assay for SARS-CoV-2 in a respiratory tract sample.

Transthoracic echocardiography was performed using a VIVID-E9 ultrasound machine (GE).

Serum, plasma, and whole blood samples were obtained routinely at the time of admission.

Complete blood count, coagulation tests, inflammatory markers [like circulating levels of Creactive protein (CRP), Procalcitonin (PCT), Ferritin, Interleukin-6 (IL-6)], N-terminal pro Btype natriuretic peptide, and creatinine levels in blood were measured among other tests (Table 2 ).

At follow-up full pulmonary function tests (PFTs), electrocardiography, and transthoracic echocardiography were performed. Furthermore, blood samples were taken; and healthrelated quality of life was assessed. With support of a trained study team, patients answered different clinical questionnaires to assess various aspects of their quality of life including: Patient Health Questionnaire 9 (PHQ-9) of depression, [26] Generalized Anxiety Disorder 7 (GAD-7), [27] St. George's Respiratory Questionnaire (SGRQ) (which is scaled from 0 representing optimal health to 100 reflecting worst health, and has three main components: symptoms component evaluates respiratory symptoms; activities component evaluates the J o u r n a l P r e -p r o o f physical activity; and the impacts component assesses social and psychological limitations), [28, 29] and EQ-5D-5L (Euro Quality of life -five Dimensions -five Levels) questionnaire, which is a descriptive system that defines health in terms of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. [30] Whole-body plethysmography (MasterLab; Viasys, Hoechberg, Germany) was performed before and after bronchodilation (including DLco measurement only after bronchodilation) according to current guidelines and recommendations. [31, 32] Samples for blood gas analyses (ABG) were taken from the arterialized earlobes of all patients while breathing room air without supplemental oxygen (ABL 800 flex; Radiometer, Copenhagen, Denmark).

All patients underwent 6-minute walk test (6MWT) without supplemental oxygen, with measurements of vital parameters including oxygen saturation on pulse oximeter (SpO2) and

Borg-scale before and after exercise according to current recommendations. [33, 34] Differences to the walk distance predicted values and lower limit of normal values (lower 95% confidence interval) were calculated for all patients. All patients with elevated D-dimer levels underwent ultrasound duplex scanning and ventilation/perfusion (V/Q) scan to rule out venous thromboembolism (VTE).

Statistical analyses were performed using standard descriptive statistics including median [interquartile range], quartiles, frequencies, and percentages (%).

Between February and May 2020, a total of 57 patients with COVID-19 were discharged from the isolation ward. We describe the first 33 patients (age 64±3, 67% male) being admitted to our outpatient clinic for follow-up examination six weeks after discharge from hospital.

Baseline characteristics, laboratory findings and symptoms at admission day are described in Tables 1,2 (Table 3) .

There was no pericardial effusion in any patient.

According to PHQ-9 and GAD-7 questionnaires, patients mostly suffered from mild depression and anxiety (PHQ-9: median = 7 [IQR: [4] [5] [6] [7] [8] [9] [10] [11] , GAD-7: median = 4 [IQR 1-9], respectively). The SGRQ test showed mainly reduced physical activity (activity score median = 54 [IQR ). Using the EQ-5D-5L, patients reported slight to moderate problems with mobility, self-care (washing or dressing), doing usual activities, pain/discomfort and anxiety/depression ( Table 4 ). Quality of life scores at admission and follow up were available in 6 patients (Table 5) . At admission, patients reported mainly moderate to severe problems J o u r n a l P r e -p r o o f with their mobility and severe pain/discomfort. At follow up, a slight to moderate level of limitation was documented.

The present case series describes follow-up data of patients with severe COVID-19 six weeks after discharge from hospital. Although patients in our cohort had some respiratory symptoms, they had no significant ventilatory limitations in the PFTs and only a mild reduction in diffusing capacity of the lungs for carbon monoxide. In the echocardiography there were no abnormalities of cardiac function or wall movement disorders, and no indicators of pulmonary hypertension. In addition, there were relevant limitations of the walk distance during exercise testing, but without exercise induced desaturation. Importantly, there were no thromboembolic events in our cohort of patients not receiving any anticoagulants. However, a significant number of patients reported to have fatigue symptoms and a low physical activity.

Autopsy data on patients who had died from COVID-19 showed different degrees of diffuse alveolar damage (DAD), with some early organization, however without marked fibrosis. [35, 36] Nevertheless, it is still unclear if this lung damage leaves prolonged lesions in the lung tissue, and how relevant these abnormalities are on the long term. A recent study reported some limitation in PFTs (mainly decrease in the values of DLco) in patients with COVID-19 at 30 days after discharge. [37] Importantly, some of these patients had very severe disease during their hospital stay and suffered not only from isolated pneumonia, but also from the different burdens of mechanical ventilation (e.g. ventilator-induced lung injury), making them prone to all sequelae of critical illness. In contrast, patients requiring mechanical ventilation were excluded in our study to eliminate presumed effects of prolonged ventilation on the shortterm follow-up outcomes; and they were evaluated after a longer period of time following discharge. Interestingly, despite the high prevalence of radiological pulmonary opacities at admission to hospital, there were no relevant limitations in the PFTs at the follow-up; even the diffusion capacity was only slightly reduced. Furthermore, no exercise-induced disturbances in gas exchange were observed. Taken together, COVID-19 per se seems not to cause prolonged pulmonary abnormalities after recovery from the acute disease which is in accordance with data from autopsy studies showing the absence of organizing interstitial fibrosis as well as other fibrotic changes even in patients suffering from ARDS associated with COVID-19 and in contrast to ARDS of different etiology. [35, 36, 38] However, whether the slightly reduced DLco reflects mild fibrosis at least in some patients cannot be answered by the data obtained in our study and should be further investigated at a later time point by pulmonary function test and imaging.

Another important finding of our follow-up analysis was that different aspects in quality of life were altered in patients after recovery from COVID-19. There was a significant tendency among the patients to suffer from fatigue symptoms with significant limitations of their mobility, which was also reflected by reduced 6MWT distance. Similar observations have been made during previous coronavirus outbreaks. In the 2003 SARS epidemic in Toronto, 10 percent of the survivors suffered from fatigue symptoms such as weakness, myalgia or headache three years later. Due to the severity of these symptoms, some patients were partly unable to carry out their previous job. [39] The explanation of these disturbances is uncertain, since there were no indicators of psychological trauma like depression or anxiety.

One explanation could be the direct interaction of the novel Coronavirus with the central nervous system (CNS) and peripheral nervous system (PNS). It is now well known that there is a wide range of CNS and PNS involvement in COVID-19; [40] and similar to other Coronaviruses, the novel virus may have caused chronic post-inflammatory CNS disturbances adversely affecting sleep, pain sensitivity, and energy which would lead to the development of fatigue syndrome. [39] Although some cardiac biomarkers were elevated at hospital admission, these values were regressive at follow-up after six weeks. A previous study showed that right ventricular function is often reduced among hospitalized COVID-19

patients. [41] However, after six weeks from discharge both left and right ventricular functions were preserved and there were no indicators of pulmonary hypertension, making a cardiac origin of the fatigue symptoms unlikely.

To the best of our knowledge, this is the first study to evaluate the risk of COVID-19-related thromboembolic diseases after recovery from the acute disease. Thromboembolic complications are quite common in severe cases, and the best marker of these complications is the D-dimer, which also has a good correlation with the severity of the disease and represents a good predictor for adverse outcomes. [42] [43] [44] In our cohort D-dimer levels were significantly elevated during active disease; with a drop at the time of follow-up. In the small fraction of patients with elevated D-dimer levels at follow-up, there was no evidence for thromboembolic diseases in the ultrasound duplex scanning and in V/Q scan. Major thrombotic events in patients with COVID-19 have been suggested as a possible cause of increased out-of-hospital sudden death episodes since COVID-19 outbreaks. [43] However, whilst this hypothesis needs to be further examined in bigger case-control studies, our findings suggest that the risk of thromboembolic complications is not increased in patients with COVID-19 being treated outside the ICU after discharge from hospital.

Hospitalized patients who suffered from severe COVID-19 and were not mechanically ventilated are unlikely to develop long-term pulmonary and cardiac impairments or J o u r n a l P r e -p r o o f Tables: Table 1 . Baseline characteristics and medical history. 

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility

Natural History of Asymptomatic SARS-CoV-2 Infection

Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Bellows, Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Clinical Features and Shortterm Outcomes of 102 Patients with Corona Virus Disease

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Guillain-Barré Syndrome Associated with SARS-CoV-2

Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

WHO Director-General's opening remarks at the media briefing on COVID

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

The PHQ-9: validity of a brief depression severity measure

The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review

The St George's Respiratory Questionnaire

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

EuroQol: the current state of play, Health policy

Standardisation of the measurement of lung volumes

Standardisation of spirometry

Reference values for the 6-min walk test in healthy subjects 20-50 years old

The 6-min walk distance in healthy subjects: reference standards from seven countries

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Autopsy in ARDS: insights into natural history

Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study

Neurological associations of COVID-19

The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) -a Systematic Echocardiographic Study

Coagulopathy in COVID-19

The unique characteristics of COVID-19 coagulopathy

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

ABBREVIATIONS: EQ-5D-5L = Euro quality of life -five dimensions -five levels; GAD-7 = generalized anxiety disorder

PHQ-9 = patient health questionnaire 9

J o u r n a l P r e -p r o o f Highlights:-Pulmonary impairment in hospitalized COVID-19 patients seems to be transient.-COVID-19 patients are unlikely to develop pulmonary impairments on follow-up.-Patients with COVID-19 often suffer from chronic fatigue following acute disease.-Exercise capacity is reduced 6 weeks after COVID-19.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f